TY - JOUR
T1 - CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart
AU - Schoger, Eric
AU - Carroll, Kelli J.
AU - Iyer, Lavanya M.
AU - McAnally, John R.
AU - Tan, Wei
AU - Liu, Ning
AU - Noack, Claudia
AU - Shomroni, Orr
AU - Salinas, Gabriela
AU - Groß, Julia
AU - Herzog, Nicole
AU - Doroudgar, Shirin
AU - Bassel-Duby, Rhonda
AU - Zimmermann, Wolfram H.
AU - Zelarayán, Laura C.
N1 - Funding Information:
This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG]) grants: (ZE900-3 to L.C. Zelarayán), the Collaborative Research Center (CRC/SFB) 1002 (Project C07 to L.C. Zelarayán, C04 and S01 to W.-H. Zimmermann and INF project to S. Nussbeck and B. Schwappach), German Heart Research Foundation, German Center for Cardiovascular Research (DZHK), DZHK Excellence Program (to S. Doroudgar), National Institute of Health (NIH) grant 5F32 HL129711-03 to K.J. Caroll, and Foundation Leducq (14CVD04; E. Olson, W.-H. Zimmermann). Funding for open access charge was provided by internal institutional funding (UMG).
Publisher Copyright:
© 2019 The Authors.
PY - 2020/1/3
Y1 - 2020/1/3
N2 - Rationale: Genome editing by CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 is evolving rapidly. Recently, second-generation CRISPR/Cas9 activation systems based on nuclease inactive dead (d)Cas9 fused to transcriptional transactivation domains were developed for directing specific guide (g)RNAs to regulatory regions of any gene of interest, to enhance transcription. The application of dCas9 to activate cardiomyocyte transcription in targeted genomic loci in vivo has not been demonstrated so far. Objective: We aimed to develop a mouse model for cardiomyocyte-specific, CRISPR-mediated transcriptional modulation, and to demonstrate its versatility by targeting Mef2d and Klf15 loci (2 well-characterized genes implicated in cardiac hypertrophy and homeostasis) for enhanced transcription. Methods and Results: A mouse model expressing dCas9 with the VPR transcriptional transactivation domains under the control of the Myh (myosin heavy chain) 6 promoter was generated. These mice innocuously expressed dCas9 exclusively in cardiomyocytes. For initial proof-of-concept, we selected Mef2d, which when overexpressed, led to hypertrophy and heart failure, and Klf15, which is lowly expressed in the neonatal heart. The most effective gRNAs were first identified in fibroblast (C3H/10T1/2) and myoblast (C2C12) cell lines. Using an improved triple gRNA expression system (TRISPR [triple gRNA expression construct]), up to 3 different gRNAs were transduced simultaneously to identify optimal conditions for transcriptional activation. For in vivo delivery of the validated gRNA combinations, we employed systemic administration via adeno-associated virus serotype 9. On gRNA delivery targeting Mef2d expression, we recapitulated the anticipated cardiac hypertrophy phenotype. Using gRNA targeting Klf15, we could enhance its transcription significantly, although Klf15 is physiologically silenced at that time point. We further confirmed specific and robust dCas9VPR on-target effects. Conclusions: The developed mouse model permits enhancement of gene expression by using endogenous regulatory genomic elements. Proof-of-concept in 2 independent genomic loci suggests versatile applications in controlling transcription in cardiomyocytes of the postnatal heart.
AB - Rationale: Genome editing by CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 is evolving rapidly. Recently, second-generation CRISPR/Cas9 activation systems based on nuclease inactive dead (d)Cas9 fused to transcriptional transactivation domains were developed for directing specific guide (g)RNAs to regulatory regions of any gene of interest, to enhance transcription. The application of dCas9 to activate cardiomyocyte transcription in targeted genomic loci in vivo has not been demonstrated so far. Objective: We aimed to develop a mouse model for cardiomyocyte-specific, CRISPR-mediated transcriptional modulation, and to demonstrate its versatility by targeting Mef2d and Klf15 loci (2 well-characterized genes implicated in cardiac hypertrophy and homeostasis) for enhanced transcription. Methods and Results: A mouse model expressing dCas9 with the VPR transcriptional transactivation domains under the control of the Myh (myosin heavy chain) 6 promoter was generated. These mice innocuously expressed dCas9 exclusively in cardiomyocytes. For initial proof-of-concept, we selected Mef2d, which when overexpressed, led to hypertrophy and heart failure, and Klf15, which is lowly expressed in the neonatal heart. The most effective gRNAs were first identified in fibroblast (C3H/10T1/2) and myoblast (C2C12) cell lines. Using an improved triple gRNA expression system (TRISPR [triple gRNA expression construct]), up to 3 different gRNAs were transduced simultaneously to identify optimal conditions for transcriptional activation. For in vivo delivery of the validated gRNA combinations, we employed systemic administration via adeno-associated virus serotype 9. On gRNA delivery targeting Mef2d expression, we recapitulated the anticipated cardiac hypertrophy phenotype. Using gRNA targeting Klf15, we could enhance its transcription significantly, although Klf15 is physiologically silenced at that time point. We further confirmed specific and robust dCas9VPR on-target effects. Conclusions: The developed mouse model permits enhancement of gene expression by using endogenous regulatory genomic elements. Proof-of-concept in 2 independent genomic loci suggests versatile applications in controlling transcription in cardiomyocytes of the postnatal heart.
KW - cardiomyocytes
KW - proof of concept model
KW - transcription activation
KW - transcriptional regulatory elements
UR - http://www.scopus.com/inward/record.url?scp=85077475395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077475395&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.118.314522
DO - 10.1161/CIRCRESAHA.118.314522
M3 - Article
C2 - 31730408
AN - SCOPUS:85077475395
SN - 0009-7330
VL - 126
SP - 6
EP - 24
JO - Circulation research
JF - Circulation research
IS - 1
ER -